Pioneering programmable off-the-shelf therapeutics to enhance the immune system and fight disease with precision, safety and scalability
Our platform enables readily available, cost-efficient therapeutics that remain competitive with existing biologics while eliminating the complex, patient-specific manufacturing challenges of cell therapies
Our proprietary approach enables durable therapeutic effects through low immunogenic epigenetic editing platform, achieving long-lasting gene modulation without DNA damage or risk of secondary malignancies
This approach enables access to multiple targets, both traditionally druggable and previously undruggable, to reactivate the patient's natural anti-tumor immune response